在患有固体或血液学先进瘤的患者中,tislelizumab的临床剂量推理
Tian Yu1, Xiangyu Liu1, Chi-Yuan Wu1
1BeiGene USA, Inc., San Mateo, California, USA.
Clinical and translational science
|March 22, 2024
概括
抗PD-1抗体Tislelizumab在治疗晚期癌症的不同剂量中显示出一致的疗效和安全性. 推的200mg q3w疗程平衡了临床益处与患者的剂量便利性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理动力学 药理动力学
背景情况:
- 蒂斯莱利祖马布是一种抗编程细胞死亡蛋白1 (PD-1) 单克隆抗体.
- 它在各种癌症症状中显示出生存益处.
研究的目的:
- 呈现临床理由和数据支持推的tislelizumab剂量.
- 为了评估晚期瘤患者的剂量方案.
主要方法:
- 第一阶段,首次在人体上进行,剂量确定研究 (BGB-A317-001) 评估了多种tislelizumab剂量方案.
- 从四个I/II期研究中进行了聚合暴露-反应 (E-R) 分析.
主要成果:
- 在测试剂量队列中观察到类似的客观响应率 (ORR).
- 在所有剂量范围内,安全结果是可比的.
- 在tislelizumab暴露和ORR或安全终点之间没有发现显著的相关性.
结论:
- 推的tislelizumab剂量为200mg q3w,由疗效,安全性和暴露-反应数据支持.
- 这种疗法为多种癌症症状提供了一个方便的剂量计划.
相关概念视频
01:27Tumor Immunotherapy
523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K